Pentixapharm Holding AG (ETR:PTP)

Market Cap	49.94M -51.2%
Revenue (ttm)	1.52M -63.6%
Net Income	-26.50M
EPS	-1.07
Shares Out	24.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	282
Average Volume	40,572
Open	2.115
Previous Close	2.050
Day's Range	2.015 - 2.115
52-Week Range	1.300 - 4.000
Beta	n/a
RSI	49.19
Earnings Date	Mar 26, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 64
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PTP

Financial Performance

In 2024, Pentixapharm Holding AG's revenue was 1.40 million, a decrease of -78.47% compared to the previous year's 6.51 million. Losses were -13.98 million, 82.9% more than in 2023.